Moderna, Inc. $MRNA Position Raised by Voya Investment Management LLC

Voya Investment Management LLC grew its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 381,195 shares of the company’s stock after acquiring an additional 22,843 shares during the quarter. Voya Investment Management LLC owned about 0.10% of Moderna worth $73,407,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in Moderna during the 2nd quarter valued at about $2,142,877,000. Theleme Partners LLP bought a new position in Moderna in the 2nd quarter worth about $564,272,000. Merck & Co. Inc. acquired a new stake in shares of Moderna in the second quarter valued at approximately $161,642,545. Bamco Inc. NY acquired a new stake in shares of Moderna in the second quarter valued at approximately $139,317,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Moderna in the second quarter valued at approximately $119,168,000. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on MRNA shares. Rothschild & Co Redburn lowered Moderna from a “neutral” rating to a “sell” rating and increased their price objective for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. JPMorgan Chase & Co. lifted their target price on Moderna from $77.00 to $102.00 and gave the company an “underweight” rating in a research note on Tuesday. Deutsche Bank initiated coverage on Moderna in a research note on Friday, August 28th. They set a “hold” rating and a $125.00 target price on the stock. CLSA upgraded Moderna to an “outperform” rating in a research report on Friday, August 28th. Finally, William Blair cut Moderna from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 27th. Six research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $120.25.

Get Our Latest Report on MRNA

Insider Buying and Selling

In other news, President Stephen Hoge sold 40,294 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the transaction, the president owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 275,626 shares of company stock valued at $50,776,076 over the last three months. Company insiders own 10.80% of the company’s stock.

Recent Moderna Headlines

Investors following MRNA have been watching these headlines:

  • Neutral Sentiment: Morgan Stanley raised its price target from $95 to $200 but kept an “equal weight” rating, suggesting the firm sees limited near-term upside at the cited share price despite the higher target. Analyst outlook
  • Negative Sentiment: President Stephen Hoge sold shares on November 16 and 17, totaling about $16.9 million. The transactions were made under a pre-arranged Rule 10b5-1 plan, which tempers their significance, but insider sales can still weigh on sentiment. SEC filing
  • Negative Sentiment: Moderna’s shares have been in a losing streak after a very large year-to-date rally, raising the prospect of profit-taking and higher expectations. The vaccine trial’s strong results have not prevented the stock from weakening, suggesting investors may be focused on valuation or how quickly the program can translate into revenue. Stock performance article

Moderna Trading Down 4.8%

Moderna stock opened at $196.79 on Thursday. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The stock has a market capitalization of $79.63 billion, a PE ratio of -27.72 and a beta of 1.16. The firm has a 50 day simple moving average of $205.61 and a 200-day simple moving average of $98.82.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.51) earnings per share. As a group, equities research analysts expect that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

See Also

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.